References
- Griffin L. Non-melanoma skin cancer. Clin Med. 2016;16:62–65.
- Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80:303–317.
- Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35–48.
- Orchard GE, Wojcik W, Shams F, et al. Pan-cytokeratin markers for rapid frozen section immunocytochemistry from head and facial Mohs cases of basal cell carcinoma: a comparison and evaluation to determine the marker of choice. Br J Biomed Sci. 2016;72:61–66.
- Mansouri B, Bicknell LM, Hill D, et al. Mohs micrographic surgery for the management of cutaneous malignancies. Facial Plast Surg Clin North Am. 2017;25:291–301.
- Titford M. The long history of hematoxylin. Biotech Histochem. 2005;80:73–78.
- GE O. Hematoxylin – the story of the blues. Br J Biomed Sci. 2018;75:149–152.
- UKNEQAS. Staining criteria handbook Mohs’ procedure. 2 ed. Gateshead: UKNEQAS CPT; 2017.
- Bancroft J, Suvarna K, Layton C, et al. Bancroft’s theory and practice of histological techniques. Oxford: Elsevier; 2015. 126–138.
- Larson K, Ho HH, Anumolu PL, et al. Hematoxylin and eosin tissue stain in mohs micrographic surgery: a review. Dermatol Surg. 2011;37:1089–1099.